ArticleLeukemia2026

Off-trial outcomes of zanubrutinib in Waldenström macroglobulinemia: the prognostic impact of CXCR4 and TP53 alterations.

Alberto Guijosa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.